- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06414174
Comparison Between Split Septum and Mechanical Valve Needleless Connector in Preterm Babies
Comparison Between Split Septum and Mechanical Valve Needleless Connector in Preventing Central Line-Associated Bloodstream Infections in Very Preterm Babies or Birth Weight <1500 Grams at Cipto Mangunkusumo Hospital Neonatology Unit
The goal of this clinical trial study is to compare the effectiveness between split septum and mechanical valve needleless connector in very preterm babies (or under 1500 grams)
The main questions it aims to answer are:
- What is the incidence of Central Line-Associated Bloodstream Infections when using a split septum connector?
- What is the incidence of Central Line-Associated Bloodstream Infections when using a mechanical valve connector?
- What is the ratio length of stay between babies with birth weight < 1500 grams who use split septum connector and mechanical valve?
- What is the ratio incidence of mortality due to sepsis of babies with birth weight < 1500 grams who use split septum connector and mechanical valve?
Participants will be observed for two weeks after insertion of central line. They will be taken blood sample for culture and sepsis marker panel.
Researchers will compare split septum group and mechanical valve group to see if there is a central line associated bloodstream infections
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Putri Maharani Tristanita Marsubrin, Doctoral
- Phone Number: +62 8128126640
- Email: putristanita2806@yahoo.com
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Preterm neonates with gestational age less than and equal to 32 weeks
- Birth weight less than 1500 gram
- Neonates indicated to use central line access
- Parents are willing to participate in this study and has filled and signed the informed consent letter
Exclusion Criteria:
- Neonates who are previously diagnosed as CLABSI
- Neonates who has other focus of infection that are diagnosed before the recruitment
- Suffer from congenital abnormalities
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Very preterm neonates or birth weight < 1500 gram receiving split septum needleless connector
Very preterm neonates or birth weight < 1500 gram who needs central line access will use split septum mechanism for their needleless connector
|
Participants in this study are limited to very preterm neonates or neonates with birth weight under 1500 grams.
Split septum mechanism is still widely use in Indonesia, therefore the use of mechanical valve mechanism as needleless connector for central line access in very preterm neonates have never been tested.
|
Active Comparator: Very preterm neonates or birth weight < 1500 gram receiving mechanical valve needleless connector
Very preterm neonates or birth weight < 1500 gram who needs central line access will use mechanical valve for their needleless connector
|
Participants in this study are limited to very preterm neonates or neonates with birth weight under 1500 grams.
Split septum mechanism is still widely use in Indonesia, therefore the use of mechanical valve mechanism as needleless connector for central line access in very preterm neonates have never been tested.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Central Line Associated Bloodstream Infection (CLABSI)
Time Frame: From the date of central line insertion until the date of documented infection, whichever came first, assessed up to 2 weeks
|
The incidence of CLABSI are proven by clinical symptoms followed by positive blood culture taken at two different site, consist of peripheral and central site
|
From the date of central line insertion until the date of documented infection, whichever came first, assessed up to 2 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Length of stay
Time Frame: From the date of central line insertion until the date of discharged, whichever came first, assessed up to 2 weeks
|
The duration which the subject is hospitalized
|
From the date of central line insertion until the date of discharged, whichever came first, assessed up to 2 weeks
|
Death
Time Frame: From the date of central line insertion until the date of death, whichever came first, assessed up to 2 weeks
|
Incidence of death because of sepsis
|
From the date of central line insertion until the date of death, whichever came first, assessed up to 2 weeks
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NeedlelessInd
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sepsis, Neonatal
-
Jip GroenInBiomeRecruitingMicrobial Colonization | Neonatal Infection | Neonatal Sepsis, Early-Onset | Microbial Disease | Clinical Sepsis | Culture Negative Neonatal Sepsis | Neonatal Sepsis, Late-Onset | Culture Positive Neonatal SepsisNetherlands
-
Yale UniversityWithdrawnA Pilot Randomized Controlled Trial for Antibiotic Exposure in Neonatal Sepsis Using Neutrophil CD64Neonatal Early-onset Sepsis | Neonatal Late-onset SepsisUnited States
-
Franciscus GasthuisErasmus Medical CenterCompletedNeonatal Infection | Neonatal SEPSISNetherlands
-
prof. dr. Frans B. PlötzDutch Society of Pediatrics; Zorgevaluatie Nederland; Care4Neo; everywhereIMRecruitingEOS | Early-Onset Sepsis, NeonatalNetherlands
-
Drugs for Neglected DiseasesUniversiteit Antwerpen; PENTA Foundation; St George's, University of LondonCompletedNeonatal SEPSISBangladesh, Uganda, Thailand, South Africa, Italy, Greece, India, Brazil, China, Kenya, Vietnam
-
Assiut UniversityUnknown
-
Assiut UniversityUnknown
-
Sohag UniversityNot yet recruiting
-
Assiut UniversityUnknown
-
London School of Hygiene and Tropical MedicineCompletedNeonatal SEPSISBurkina Faso, Gambia